Cargando…

Fetal Toxicity of Immunosuppressive Drugs in Pregnancy

Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponticelli, Claudio, Moroni, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306731/
https://www.ncbi.nlm.nih.gov/pubmed/30558290
http://dx.doi.org/10.3390/jcm7120552
_version_ 1783382844131770368
author Ponticelli, Claudio
Moroni, Gabriella
author_facet Ponticelli, Claudio
Moroni, Gabriella
author_sort Ponticelli, Claudio
collection PubMed
description Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal risks. Some immunosuppressive drugs are teratogenic and should be replaced even before the pregnancy, while other drugs need to be managed with caution to prevent fetal risks, including miscarriage, intrauterine growth restriction, prematurity, and low birth weight. In particular, the increasing use of biologic agents raises the question of their compatibility with reproduction. In this review we present data on the indication and safety in pregnancy of the most frequently used immunosuppressive drugs.
format Online
Article
Text
id pubmed-6306731
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63067312019-01-02 Fetal Toxicity of Immunosuppressive Drugs in Pregnancy Ponticelli, Claudio Moroni, Gabriella J Clin Med Review Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal risks. Some immunosuppressive drugs are teratogenic and should be replaced even before the pregnancy, while other drugs need to be managed with caution to prevent fetal risks, including miscarriage, intrauterine growth restriction, prematurity, and low birth weight. In particular, the increasing use of biologic agents raises the question of their compatibility with reproduction. In this review we present data on the indication and safety in pregnancy of the most frequently used immunosuppressive drugs. MDPI 2018-12-15 /pmc/articles/PMC6306731/ /pubmed/30558290 http://dx.doi.org/10.3390/jcm7120552 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ponticelli, Claudio
Moroni, Gabriella
Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title_full Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title_fullStr Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title_full_unstemmed Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title_short Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
title_sort fetal toxicity of immunosuppressive drugs in pregnancy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306731/
https://www.ncbi.nlm.nih.gov/pubmed/30558290
http://dx.doi.org/10.3390/jcm7120552
work_keys_str_mv AT ponticelliclaudio fetaltoxicityofimmunosuppressivedrugsinpregnancy
AT moronigabriella fetaltoxicityofimmunosuppressivedrugsinpregnancy